Form 4: Phio Pharmaceuticals CEO Acquires Additional Shares
SEC Form 4 Filing
Robert J. Bitterman, President and CEO of Phio Pharmaceuticals Corp., purchased 1,000 shares of common stock at $0.74 per share on June 7, 2024.
Summary
- On June 7, 2024, Robert J. Bitterman, the President and CEO of Phio Pharmaceuticals Corp., acquired 1,000 shares of the company's common stock.
- The purchase price was $0.74 per share.
- Following the transaction, Bitterman directly owns 20,990 shares of Phio Pharmaceuticals Corp., which includes shares of common stock underlying unvested restricted stock units.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is a positive signal, but the quantity is relatively small.
Positives
- The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider transactions are closely monitored by investors as they can provide insights into management's perspective on the company's value and future performance. A purchase by the CEO is generally seen as a positive sign.
Stakeholder Impact
- The CEO's stock purchase may positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/07/2024 | Date of stock purchase transaction |
| 06/11/2024 | Date of Form 4 filing |
Keywords
Phio Pharmaceuticals, Robert Bitterman, stock purchase, Form 4, insider trading, ownership, shares
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.